Boston Scientific strategy focus, shares hold in S&P 500 healthcare group

Boston Scientific is a mid-cap S&P 500 healthcare name with a steady position in minimally invasive medical devices. Saturday’s angle is the long-term strategy behind the shares and how the business model sits within the wider medtech peer group.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-29, 11:54.

Boston Scientific (US10117L1017) is a long-established S&P 500 healthcare stock with a focus on minimally invasive medical technology and a primary listing on the NYSE under the ticker BSX. The company sits in the same broad medtech peer group as Abbott Laboratories and Medtronic, with a market capitalization in the mid tens of billions of dollars.

Position in the medtech peer group

Boston Scientific’s shares represent one of several large US medtech names that cover cardiology, endoscopy and neuromodulation alongside peers such as Medtronic and Abbott Laboratories. The company’s equity is part of the S&P 500 index, which provides broad US institutional investor access.

Analyst and market-data aggregators typically classify Boston Scientific under the health care equipment and supplies segment within GICS, reflecting its portfolio of implantable and disposable products rather than pharmaceuticals. Most consensus pages present BSX as a mid-cap to lower large-cap stock by US standards, despite its global reach.

Long-term strategy and business model

Boston Scientific’s long-term strategy centers on building scale across focused therapy areas including interventional cardiology, peripheral interventions, rhythm management, endoscopy and urology. The business model relies on recurring device sales to hospitals and clinics, often supported by training and clinical evidence.

In cardiology, Boston Scientific competes directly with Abbott and Medtronic in drug-eluting stents, structural heart therapies and electrophysiology systems. This competition shapes capital allocation priorities, with investment directed toward differentiated technologies that can command premium pricing and strong clinical outcomes in head-to-head trials.

The product behind the stock

One representative Boston Scientific product line is its drug-eluting coronary stents, which are designed to keep arteries open after angioplasty procedures and reduce the risk of restenosis. These stents are sold primarily to hospitals and cardiac catheterization labs as part of the interventional cardiology portfolio.

Where the stock trades today

The Boston Scientific shares (US10117L1017) most recently traded on the NYSE at about 44.23 US dollars in regular hours, with a narrow pre-market indication around 44.28 US dollars on the latest available data.

Key data on the Boston Scientific shares

• Company: Boston Scientific Corp.
• ISIN: US10117L1017
• WKN: 884113
• Ticker: BSX
• Trading venue: NYSE
• Price (as of 2026-06-28, 21:30): 44.23 USD
• Market cap: around 60 billion USD (as of 2026-06-28)
• Sector / industry: Health Care Equipment & Supplies
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This text is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Past performance of financial instruments is not a reliable indicator of future results.